AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2074205 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retransfusion)
Number of subjects: 20
Study 6157007 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine therapy (2 mg/kg body weight daily)
Number of subjects: 56
Study 6157007 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 56
Study 30787666 — intervention group
Group type: EXPERIMENTAL
Intervention: 60/60 s LV-HIIT
Number of subjects: 10
Study 30787666 — intervention group
Group type: COMPARATOR
Intervention: 30/30 s LV-HIIT
Number of subjects: 10
Study 28521540 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 28521540 — intervention group
Group type: COMPARATOR
Intervention: LMWH/VKA therapy
Number of subjects: 0
Study 25977516 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-diagnosed sleep apnea (PDSA)
Number of subjects: 4395
Study 25977516 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual snoring (HS)
Number of subjects: 4395
Study 25977516 — intervention group
Group type: COMPARATOR
Intervention: Neither HS nor PDSA (unaffected)
Number of subjects: 4395
Study 24015632 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy and adenoidectomy
Number of subjects: 113
Study 24015632 — intervention group
Group type: COMPARATOR
Intervention: Coblation adenoidectomy only
Number of subjects: 113
Study 24015632 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic tonsillitis group
Number of subjects: 113
Study 24015632 — intervention group
Group type: COMPARATOR
Intervention: Non-chronic tonsillitis group
Number of subjects: 113
Study 21301819 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249 (10 mg)
Number of subjects: 25
Study 21301819 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249 (50 mg)
Number of subjects: 25
Study 21301819 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 25
Study 21301819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19585107 — intervention group
Group type: EXPERIMENTAL
Intervention: acute tryptophan depletion (ATD)
Number of subjects: 24
Study 19585107 — intervention group
Group type: COMPARATOR
Intervention: tryptophan-supplemented control mixture
Number of subjects: 24
Study 17722823 — intervention group
Group type: EXPERIMENTAL
Intervention: Methycobal 250 microg intramuscular injection plus acupuncture at Guanyuan (CV 4), Shenshu (BL 23), Ciliao (BL 32), Huiyang (BL 35), once every day
Number of subjects: 70
Study 17722823 — intervention group
Group type: COMPARATOR
Intervention: Methycobal 250 microg intramuscular injection, once every other day
Number of subjects: 70
Study 17722823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Methycobal with and without acupuncture)
Number of subjects: 70
Study 17722823 — intervention group
Group type: EXPERIMENTAL
Intervention: Methycobal plus acupuncture
Number of subjects: 70
Study 15096240 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral injection of radio‐opaque dye (10 ml) with co‐administration of 20 ml of local anaesthetics, ventral to the endothoracic fascia
Number of subjects: 28
Study 15096240 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral injection of radio‐opaque dye (10 ml) without co‐administration of local anaesthetics, dorsal to the endothoracic fascia
Number of subjects: 28
Study 11319433 — intervention group
Group type: EXPERIMENTAL
Intervention: Open wedge medial osteotomy
Number of subjects: 33
Study 9876348 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg i.v.)
Number of subjects: 11
Study 9876348 — intervention group
Group type: COMPARATOR
Intervention: Saline (as control)
Number of subjects: 11
Study 9876348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Naloxone and Saline)
Number of subjects: 11
Study 9876348 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (25 micrograms i.v.)
Number of subjects: 11
Study 8031733 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MJ meal
Number of subjects: 8
Study 8031733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MJ meal
Number of subjects: 8
Study 8031733 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MJ meal
Number of subjects: 8
Study 2597607 — intervention group
Group type: EXPERIMENTAL
Intervention: Imotest multiple puncture tuberculin test
Number of subjects: 0
Study 2597607 — intervention group
Group type: COMPARATOR
Intervention: Heaf test
Number of subjects: 0
Study 2597607 — intervention group
Group type: COMPARATOR
Intervention: Mantoux test
Number of subjects: 0
Study 30060030 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc pleurodesis
Number of subjects: 0
Study 30060030 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters
Number of subjects: 0
Study 30060030 — intervention group
Group type: EXPERIMENTAL
Intervention: LENT score
Number of subjects: 0
Study 30060030 — intervention group
Group type: EXPERIMENTAL
Intervention: Brims' prognostic score
Number of subjects: 0
Study 30060030 — intervention group
Group type: COMPARATOR
Intervention: Oncological therapies
Number of subjects: 0
Study 30060030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue biopsy
Number of subjects: 0
Study 28927917 — intervention group
Group type: EXPERIMENTAL
Intervention: Active leisure contact sports (group A)
Number of subjects: 204
Study 28927917 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (group B)
Number of subjects: 204
Study 25619410 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL‐M) 40 mg once a day (QD), titrated to 80 mg at week 4, with optional addition of chlorthalidone (CLD) 25 mg QD (weeks 8-22) if required.
Number of subjects: 418
Study 25619410 — intervention group
Group type: COMPARATOR
Intervention: Azilsartan medoxomil (AZL‐M)
Number of subjects: 418
Study 25619410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 23789212 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla oil treatment for 8 weeks
Number of subjects: 0
Study 23789212 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21971472 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 21971472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18653347 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone interbody cage
Number of subjects: 0
Study 18653347 — intervention group
Group type: COMPARATOR
Intervention: Autologous iliac bone grafting with anterior plate
Number of subjects: 0
Study 16645290 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-standardized acupuncture (12 sessions, 6 predefined basic points, optional additional points)
Number of subjects: 302
Study 16645290 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized minimal acupuncture (superficial needling of at least 5 of 10 predefined, distant non-acupuncture points)
Number of subjects: 302
Study 16645290 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 302
Study 14639962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient sleep
Number of subjects: 2000
Study 14639962 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2000
Study 14639962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking
Number of subjects: 2000
Study 14639962 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking
Number of subjects: 2000
Study 14639962 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about the harm of smoking
Number of subjects: 2000
Study 10682965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Number of subjects: 19
Study 10682965 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year use of dorzolamide
Number of subjects: 19
Study 10682965 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 19
Study 9015905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal surgery with nasal pack removed after two hours
Number of subjects: 90
Study 9015905 — intervention group
Group type: COMPARATOR
Intervention: Nasal surgery with longer duration of nasal packing
Number of subjects: 90
Study 9015905 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal resection group
Number of subjects: 90
Study 1721574 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention effect (Md) for 1 kHz tones
Number of subjects: 23
Study 1721574 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention effect (Md) for 3 kHz tones
Number of subjects: 23
Study 1721574 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention effect (Md) in experiment 2
Number of subjects: 23
Study 1721574 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of Md source
Number of subjects: 23
Study 1721574 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of exogenous evoked response components
Number of subjects: 23
Study 6343164 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery
Number of subjects: 34
Study 31525581 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA)
Number of subjects: 21
Study 31525581 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study 28262499 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - 2 hours of training
Number of subjects: 9
Study 28262499 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - 1 hour of training
Number of subjects: 9
Study 28262499 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (G3) - no practical training
Number of subjects: 9
Study 25186180 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia‐coli‐produced recombinant human bone morphogenetic protein 2 (ErhBMP‐2) with a biphasic calcium phosphate (BCP) carrier
Number of subjects: 41
Study 25186180 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone
Number of subjects: 41
Study 24477367 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly covered antireflux metal stents (pcARMS)
Number of subjects: 112
Study 24477367 — intervention group
Group type: COMPARATOR
Intervention: Standard uncovered self‐expandable metal stents (ucSEMS)
Number of subjects: 112
Study 21950578 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 56
Study 21950578 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate 400 mg/day
Number of subjects: 56
Study 19679275 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for FCD type II
Number of subjects: 0
Study 19679275 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment for FCD type II
Number of subjects: 0
Study 17294225 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 31
Study 17294225 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisone
Number of subjects: 31
Study 15026437 — intervention group
Group type: EXPERIMENTAL
Intervention: Free smoke alarm installation
Number of subjects: 0
Study 11573916 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist protectors (braced group)
Number of subjects: 5029
Study 11573916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wrist protectors)
Number of subjects: 5029
Study 9043731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate (12.5, 25, 50, or 100 mg)
Number of subjects: 337
Study 9043731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate
Number of subjects: 337
Study 9043731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 7911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin 3 mg
Number of subjects: 11
Study 7911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin 6 mg
Number of subjects: 11
Study 7911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin 12 mg
Number of subjects: 11
Study 7911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin (all doses)
Number of subjects: 11
Study 7911057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3328105 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of Prednisone (3960 mg over 54 days, initial dose 200 mg per day)
Number of subjects: 0
Study 3328105 — intervention group
Group type: COMPARATOR
Intervention: Medium doses of Prednisone (initial dose 60 mg)
Number of subjects: 0
Study 29921942 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Non-Contrast (VNC)-CT
Number of subjects: 29
Study 29921942 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT (CT)
Number of subjects: 29
Study 27119427 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP)
Number of subjects: 60
Study 27119427 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB (priming with suspended red blood cells, plasma and albumin)
Number of subjects: 60
Study 24462581 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250mg daily
Number of subjects: 177
Study 24462581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 24065295 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density catechins
Number of subjects: 17
Study 24065295 — intervention group
Group type: COMPARATOR
Intervention: Low-density catechins
Number of subjects: 17
Study 24065295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20005081 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin-reuptake inhibitors (SSRIs) for 52 weeks
Number of subjects: 10
Study 20005081 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 10
Study 17498312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling method based on conduction, namely immersion in iced water
Number of subjects: 556
Study 17498312 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐invasive, evaporative, or conductive‐based cooling techniques
Number of subjects: 556
Study 17498312 — intervention group
Group type: COMPARATOR
Intervention: Cooling techniques (various)
Number of subjects: 556
Study 17498312 — intervention group
Group type: COMPARATOR
Intervention: Cooling techniques
Number of subjects: 556
Study 17498312 — intervention group
Group type: COMPARATOR
Intervention: Circulatory alterations in heatstroke
Number of subjects: 556
Study 17498312 — intervention group
Group type: COMPARATOR
Intervention: Myocardial failure
Number of subjects: 556
Study 15354980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hirudin (initial bolus application of 2-2-5 microg/kg, adjusted in 2 microg/kg bolus steps)
Number of subjects: 26
Study 15354980 — intervention group
Group type: COMPARATOR
Intervention: Continuous heparin (250 IU/h, adjusted in 125 IU/h steps)
Number of subjects: 26
Study 15354980 — intervention group
Group type: COMPARATOR
Intervention: Continuous heparin
Number of subjects: 26
Study 11543749 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride
Number of subjects: 150
Study 11543749 — intervention group
Group type: EXPERIMENTAL
Intervention: Valethamate bromide
Number of subjects: 150
Study 11543749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 150
Study 9924221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine with fentanyl
Number of subjects: 0
Study 9924221 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 0
Study 7918131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine 6 mg/kg
Number of subjects: 12
Study 7918131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine 12 mg/kg
Number of subjects: 12
Study 7918131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine 24 mg/kg
Number of subjects: 12
Study 7918131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine 48 mg/kg
Number of subjects: 12
Study 7918131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2843201 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 11
Study 2843201 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 11
Study 2843201 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg
Number of subjects: 11
Study 2843201 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (all doses)
Number of subjects: 11
Study 2843201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29722468 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 50
Study 29722468 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent epicardial and endocardial ablation procedure (CVP)
Number of subjects: 50
Study 27749754 — intervention group
Group type: EXPERIMENTAL
Intervention: OTO‐104 (12 mg dexamethasone)
Number of subjects: 154
Study 27749754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 24750029 — intervention group
Group type: EXPERIMENTAL
Intervention: Peel-off facial mask with 5% w/w soybean extract fermented by Bifidobacterium animale
Number of subjects: 0
Study 24750029 — intervention group
Group type: COMPARATOR
Intervention: Oil-in-water emulsion
Number of subjects: 0
Study 23820656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 160
Study 23820656 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 160
Study 21227010 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg active TA(1)
Number of subjects: 25
Study 21227010 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg recombinant TA(1)
Number of subjects: 25
Study 21227010 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 mg recombinant TA(1)
Number of subjects: 25
Study 19108666 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine monotherapy
Number of subjects: 9
Study 19108666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination paroxetine-divalproex sodium therapy
Number of subjects: 9
Study 16757447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral body image therapy
Number of subjects: 30
Study 15291906 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IgE monotherapy
Number of subjects: 221
Study 15291906 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT and anti-IgE combined treatment
Number of subjects: 221
Study 15291906 — intervention group
Group type: COMPARATOR
Intervention: SIT grass pollen monotherapy
Number of subjects: 221
Study 15291906 — intervention group
Group type: COMPARATOR
Intervention: SITbirch + placebo
Number of subjects: 221
Study 11211468 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (transmyocardial revascularization and percutaneous myocardial revascularization)
Number of subjects: 0
Study 9767511 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheterization (UC)
Number of subjects: 33
Study 9767511 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic bladder aspiration (SPA)
Number of subjects: 33
Study 7908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg
Number of subjects: 12
Study 7908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 12
Study 7908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 12
Study 7908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 100 mg
Number of subjects: 12
Study 7908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12
Study 7908256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3276296 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage after thyroid surgery
Number of subjects: 150
Study 3276296 — intervention group
Group type: COMPARATOR
Intervention: No drainage after thyroid surgery
Number of subjects: 150
Study 31578889 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (10 weeks, 10 to 12 sessions, using 19-channel EEG, training parameters based on each child's peak alpha frequency)
Number of subjects: 48
Study 31578889 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 48
Study 31503028 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises along with self-care training
Number of subjects: 32
Study 31503028 — intervention group
Group type: COMPARATOR
Intervention: Self-care training
Number of subjects: 32
Study 29042376 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed transition using the Transition Readiness and Appropriateness Measure score summary as a decision aid
Number of subjects: 1050
Study 29042376 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1050
Study 29042376 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed transition
Number of subjects: 1050
Study 26572788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated prevention programs (NCPP)
Number of subjects: 13
Study 23601463 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf blood extract gel
Number of subjects: 12
Study 23601463 — intervention group
Group type: COMPARATOR
Intervention: Autologous serum
Number of subjects: 12
Study 21601979 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Palmitoylethanolamine-transpolydatin 400 mg + 40 mg twice a day for 3 months
Number of subjects: 61
Study 21601979 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day for 7 consecutive days
Number of subjects: 61
Study 21601979 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 61
Study 19843672 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE sheddase activity measurement in HNC tissues
Number of subjects: 0
Study 19843672 — intervention group
Group type: EXPERIMENTAL
Intervention: siRNA silencing of TACE
Number of subjects: 0
Study 19843672 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE protein expression measurement
Number of subjects: 0
Study 16388198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOLs (Acrysof; Alcon)
Number of subjects: 26
Study 16388198 — intervention group
Group type: COMPARATOR
Intervention: Plate-haptic silicone IOLs (C11UB; Chiron, Bausch & Lomb)
Number of subjects: 26
Study 12623938 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (DASH‐CD)
Number of subjects: 24
Study 12623938 — intervention group
Group type: COMPARATOR
Intervention: Low‐antioxidant diet
Number of subjects: 24
Study 12623938 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 24